CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma
Status:
Recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
This phase I/Ib trial investigates the side effects of CC-486 and how well it works in
combination with lenalidomide and obinutuzumab in treating patients with CD20 positive B-cell
lymphoma that has come back (recurrent) or has not responded to treatment (refractory).
Chemotherapy drugs, such as CC-486, work in different ways to stop the growth of cancer
cells, either by killing the cells, by stopping them from dividing, or by stopping them from
spreading. Lenalidomide is a drug that alters the immune system and may also interfere with
the development of tiny blood vessels that help support tumor growth. Therefore, in theory,
it may reduce or prevent the growth of cancer cells. Obinutuzumab is a type of antibody
therapy that targets and attaches to the CD20 proteins found on follicular lymphoma cells as
well as some healthy blood cells. Once attached to the CD20 protein the obinutuzumab is
thought to work in different ways, including by helping the immune system destroy the cancer
cells and by destroying the cancer cells directly. Giving CC-486 with lenalidomide and
obinutuzumab may improve response rates, quality, and duration, and minimize adverse events
in patients with B-cell lymphoma.